Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
- Lawmakers’ Group on Pollen Allergy to Compile Opinion Paper towards Honebuto
April 9, 2024
- LDP Generic League to Soon Draw Up Proposal towards Honebuto Policy
April 9, 2024
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
- Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
- Offset Technology-Driven Cost Rise with Spending Reforms: Govt Economic Estimate
April 3, 2024
- Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
- Japan Govt Ends COVID Vaccine Supply as Emergency Program Winds Up
April 3, 2024
- Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
April 3, 2024
- Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
- Japan Revises GMP Inspection Guide after Generic Manufacturing Issues
April 2, 2024
- Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
- Drug Makers in Japan Asked to Create Pediatric Development Plans from April
April 1, 2024
- MHLW Defines “Long-Listed Products” towards Rollout of New Coverage Rule
April 1, 2024
- Kobayashi Factory Inspected over Beni-Koji Health Issue
April 1, 2024
- LDP Lawmakers Call for Penalties against “Dump and Run Away” Generic Makers
March 29, 2024
- Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
- Label Revision Ordered for CAR-T Therapies to Add New Precaution
March 29, 2024
- Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…